Characteristics | Value | |
---|---|---|
Age at SBRT (years) | ||
median (IQR) | 68 | (62–72) |
mean (range) | 68 | (52–81) |
PSA at SBRT (ug/l) | ||
median (IQR) | 3.53 | (1.48–6.86) |
mean (range) | 3.49 | (1.02–14.54) |
PSADT | ||
< 3 months | 5 | 20% |
3–6 months | 12 | 48% |
> 6 months | 8 | 32% |
Number of lymph nodes at SBRT | ||
1 | 16 | 64% |
2 | 7 | 28% |
3 | 2 | 8% |
LN localisation (n = 36) | ||
N1 | 33 | 92% |
M1a | 3 | 8% |
Largest LN diameter (mm)a | ||
median (IQR) | 10.5 | (8.5–13.5) |
mean (range) | 12.8 | (5–33) |
SBRT data (Gy) | ||
total median dose (range) | 36 | (30–45) |
median dose per fraction (range) | 12 | (10–15) |
SBRT regimen | ||
10 Gy per 3 fractions | 2 | 8% |
11 Gy per 3 fractions | 1 | 4% |
12 Gy per 3 fractions | 11 | 44% |
13 Gy per 3 fractions | 7 | 28% |
15 Gy per 3 fractions | 4 | 16% |